13D Filing: Starboard Value LP and Depomed Inc (DEPO)

Page 1 of 23

Depomed Inc (NASDAQ:DEPO): Jeffrey Smith’s Starboard Value LP filed an amended 13D.

You can check out Starboard Value LP’s latest holdings and filings here.

Please follow Starboard Value LP (if you aren’t already doing so) to get real-time email alerts whenever we publish an article about Starboard Value LP or update its stock holdings.

Follow Jeff Smith's Starboard Value LP

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
STARBOARD VALUE 4,735,295 4,735,295 4,735,295 4,735,295 7.5%
STARBOARD VALUE AND OPPORTUNITY MASTER FUND LTD 3,651,714 3,651,714 4,735,295 3,651,714 5.7%
STARBOARD VALUE AND OPPORTUNITY S 430,843 430,843 4,735,295 430,843 Less than 1%
STARBOARD VALUE AND OPPORTUNITY C 239,310 239,310 239,310 Less than 1%
STARBOARD VALUE R 239,310 239,310 239,310 Less than 1%
STARBOARD VALUE R GP 239,310 239,310 239,310 Less than 1%
STARBOARD VALUE GP 4,735,295 4,735,295 4,735,295 7.5%
STARBOARD PRINCIPAL CO 4,735,295 4,735,295 4,735,295 7.5%
STARBOARD PRINCIPAL CO GP 4,735,295 4,735,295 4,735,295 7.5%
JEFFREY C. SMITH 3,252 3,252 4,735,295 7.5%
MARK R. MITCHELL 4,735,295 7.5%
PETER A. FELD 4,735,295 7.5%
GAVIN T. MOLINELLI 3,252 Less than 1%

Follow Jeff Smith's Starboard Value LP

Page 1 of 23 – SEC Filing

UNITED STATES

SECURITIES AND EXCHANGE
COMMISSION

Washington, D.C. 20549

SCHEDULE 13D

(Rule 13d-101)

INFORMATION TO BE INCLUDED
IN STATEMENTS FILED PURSUANT

TO § 240.13d-1(a)
AND AMENDMENTS THERETO FILED PURSUANT TO

§ 240.13d-2(a)

(Amendment No. 9)1

Depomed, Inc.

(Name
of Issuer)

Common Stock,
no par value

(Title of Class of Securities)

249908104

(CUSIP Number)

JEFFREY
C. SMITH

STARBOARD
VALUE LP

777 Third Avenue, 18th Floor

New York, New York 10017

(212) 845-7977

STEVE WOLOSKY, ESQ.

OLSHAN FROME WOLOSKY LLP

1325 Avenue of the Americas

New York, New York 10019

(212) 451-2300

(Name, Address and Telephone Number of Person

Authorized to Receive Notices
and Communications)

April 3, 2018

(Date of Event Which Requires
Filing of This Statement)

If
the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule
13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following
box
¨.

Note:  Schedules
filed in paper format shall include a signed original and five copies of the schedule, including all exhibits.  See
§ 240.13d-7 for other parties to whom copies are to be sent.

1
The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to
the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided
in a prior cover page.

The information required
on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities
Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject
to all other provisions of the Act (however, see the Notes).

Follow Assertio Therapeutics Inc (NASDAQ:ASRT)

Page 1 of 23